Advanced Search

Objective assessment of manufacturing technology investments

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Robert T. Haslam and Roy Welsch. en_US Rothman, Craig Jeremy en_US
dc.contributor.other Leaders for Global Operations Program. en_US 2012-09-27T15:29:41Z 2012-09-27T15:29:41Z 2012 en_US 2012 en_US
dc.description Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering; in conjunction with the Leaders for Global Operations Program at MIT, 2012. en_US
dc.description Cataloged from PDF version of thesis. en_US
dc.description Includes bibliographical references (p. 65-67). en_US
dc.description.abstract Amgen is a biotechnology company with manufacturing plants throughout the world. New manufacturing technologies are constantly being developed and implemented in order to address cost, quality, regulation, and competitive forces. However, deciding on the technologies to implement is difficult because there is much uncertainty and the regulatory constraints of old products need to be balanced with the need of manufacturing flexibility for new products. Interviews were conducted with executives at Amgen and other biotechnology companies to understand their current decision-making processes and no gold-standard decision-making process emerged. The current process at Amgen is a business case along with net present value (NPV). However, the process has been found to be somewhat biased and decisions are often made on gut-instinct and excitement. In addition, the business case often fails to capture some of the more subjective, intangible elements of new technologies. Therefore, a technology decision-making framework based on the Analytic Hierarchy Process (AHP) is introduced. The AHP is an objective, group decision-making approach. For usability and sustainability, commercial software from Expert Choice was used in case studies to validate AHP as a decisionmaking approach within Amgen. One case study looked at options to upgrade a clinical manufacturing facility. An AHP model was analyzed simultaneously with a typical business case and NPV analysis. The AHP model allowed management to understand the more subjective areas where the options differed and therefore was a suitable approach that added value. Another case study was performed looking at choosing a standardized drug substance container where five previous analyses had been performed, but no decision made. The AHP model allowed the different criteria to be combined in one model with cross-functional input so that management could make a holistic decision. The AHP approach had many benefits and using commercial software made the process easier for users and allowed for a more sustainaible process within Amgen. en_US
dc.description.statementofresponsibility by Craig Jeremy Rothman. en_US
dc.format.extent 67 p. en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri en_US
dc.subject Sloan School of Management. en_US
dc.subject Chemical Engineering. en_US
dc.subject Leaders for Global Operations Program. en_US
dc.title Objective assessment of manufacturing technology investments en_US
dc.type Thesis en_US S.M. en_US M.B.A. en_US
dc.contributor.department Sloan School of Management. en_US
dc.contributor.department Massachusetts Institute of Technology. Dept. of Chemical Engineering. en_US
dc.contributor.department Leaders for Global Operations Program. en_US
dc.identifier.oclc 810136553 en_US

Files in this item

Name Size Format Description
810136553-MIT.pdf 9.587Mb PDF Full printable version

This item appears in the following Collection(s)

Show simple item record